Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

July

15

Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025

CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune...

23

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune...

9

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune...

8

Exagen Inc. Prices Public Offering of Common Stock

CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune...

5

Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

28

Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors

$25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides...

11

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

Delivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA...

4

Exagen Inc. to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing,...

12

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record...

12

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

The milestone demonstrates AVISE CTD’s value and adoption within the rheumatologic community, clearly demonstrating...

14

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of...

12

Exagen Inc. Reports Third Quarter 2024 Results

Expanded AVISE® CTD trailing twelve-month average selling priceReduced Adjusted EBITDA loss for first three quarters...

Recent developments

News

July

15

Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025

June

23

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

May

9

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

May

8

Exagen Inc. Prices Public Offering of Common Stock

May

5

Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

April

28

Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors

March

11

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

February

4

Exagen Inc. to Participate in Upcoming Investor Conferences

January

12

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

December

12

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

November

14

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

November

12

Exagen Inc. Reports Third Quarter 2024 Results